Industry Profile

Exosome Therapeutics and Extracellular Vesicles

Target researchers — Cell biologists, vesicle biologists, drug delivery scientists, RNA therapeutics researchers, and regenerative medicine investigators studying natural nano-delivery vehicles.

Exosome therapeutics harnesses extracellular vesicles—nano-sized lipid bilayer particles naturally secreted by cells—as both biomarkers and drug delivery vehicles, offering a biologically compatible alternative to synthetic lipid nanoparticles for nucleic acid and protein payloads. Codiak BioSciences, Evox Therapeutics, Anjarium Biosciences, and Capricor Therapeutics are advancing engineered exosome platforms through IND-enabling studies and early clinical trials, targeting oncology, neurodegeneration, and cardiovascular indications. Researchers procure ultracentrifugation systems, size-exclusion chromatography columns, nanoparticle tracking analysis instruments, electron microscopy grids for vesicle characterization, and GMP-grade cell culture media for exosome biomanufacturing. The field intersects RNA biology, synthetic biology, and advanced manufacturing, requiring specialized analytical tools including cryo-EM imaging and multi-parameter flow cytometry. Regulatory guidance on exosome characterization is evolving rapidly and Sell to Scientists CLI helps research teams identify compliant reagent suppliers, analytical CROs, and scale-up manufacturing partners for extracellular vesicle programs.

Key Companies